|
(20-November-2009) Microtek International Inc. is pleased to announce opening of a new CFIA licensed Autogenous Vaccines Manufacturing Facility. This is the only facility of its kind in Canada. This facility will allow Microtek to produce Autogenous Bacterins and help fish growers around the world to deal with their immediate and specific disease problems.
(10-March-2009) Microtek International Inc. is pleased to announce the release of Bayovac® 3.1 for sales. The vaccine is available in Chile via Bayer S. A.
(24-February-2009) Microtek International Inc. is pleased to announce a provisional licensure by Servicio Agrícola y Ganadero (SAG), Chile and a licensure for export only by Canadian Food Inspection Agency (CFIA) of Bayovac® 3.1, a novel vaccine containing protective antigens derived from Piscirickettsia salmonis, Infectious Pancreatic Necrosis Virus (IPNV) and atypical Vibrio ordalii.
(September-2008) Microtek International Inc. is pleased to announce the introduction in West Coast Canada of AdvantigenTM 4.1, a tetravalent vaccine against Furunculosis, Vibriosis and Coldwater Vibriosis. ---------This product replaced AdvantigenTM 5.1.
(May-2005) Microtek International Inc. is pleased to announce the full licensure of AdvantigenTM 5.1, a pentavalent vaccine developed by Microtek Research and Development Ltd.
(September-2004) Microtek International Inc. is pleased to announce the introduction in Chile of Bayovac® SRS, a recombinant vaccine against Piscirickettssia salmonis, developed by Microtek Research and Development Ltd.
International Mark - (398249) Bayovac |
